{"filing":{"accession_number":"0001551152-26-000023","cik":"0001551152","ticker":"ABBV","company_name":"AbbVie Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"abbv-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260731.htm"},"events":[{"id":22867,"run_id":20702,"accession_number":"0001551152-26-000023","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"AbbVie issued a press release on July 31, 2026 announcing second-quarter 2026 financial results, including net revenues of $16.990 billion (up 10.2% reported, 9.5% operational), diluted EPS of $2.03 GAAP and adjusted diluted EPS of $3.65 (up 22.9%), along with detailed portfolio performance metrics and updated full-year 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22953,"accession_number":"0001551152-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AbbVie issued a press release on July 31, 2026 announcing second-quarter 2026 financial results, including net revenues of $16.990 billion (up 10.2% reported, 9.5% operational), diluted EPS of $2.03 GAAP and adjusted diluted EPS of $3.65 (up 22.9%), along with detailed portfolio performance metrics and updated full-year 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:35:43.376323+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22953,"accession_number":"0001551152-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AbbVie issued a press release on July 31, 2026 announcing second-quarter 2026 financial results, including net revenues of $16.990 billion (up 10.2% reported, 9.5% operational), diluted EPS of $2.03 GAAP and adjusted diluted EPS of $3.65 (up 22.9%), along with detailed portfolio performance metrics and updated full-year 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:35:43.376323+00:00","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-07-31"}]}